Its addition to R-CHOP in de novo ABC DLBCL has shown promising results in phase II trials [187,188], but a recent phase III trial has shown no improvement in progression-free or overall survival in previously untreated ABC DLBCL [189]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.